LFCR Share Price Performance
US$7.64
0.33 (4.51%)
12.7% undervalued intrinsic discount
US$8.75
Fair Value
Price US$7.64
AnalystConsensusTarget US$8.75
Fair ValueUS$8.75
Share Pricen/a
Lifecore Biomedical, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
LFCR Community Narratives
AN
Fair Value US$8.75 12.7% undervalued intrinsic discount
Biopharma Partnerships And Injectable Demand Will Expand Global Reach
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Biopharma Partnerships And Injectable Demand Will Expand Global Reach
Key Takeaways Expanding partnerships, operational enhancements, and regulatory credibility are driving Lifecore's momentum in biopharma manufacturing, supporting stronger contract wins and profitability. Rising demand for injectable and HA-based drugs, along with new market entries, is broadening Lifecore's addressable market and cementing a foundation for sustained growth.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$8.75
12.7% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
10.55% p.a.
Profit Margin
15.51%
Future PE
15.82x
Share price in 2028
US$11.08
Recently Updated Narratives
AN
Biopharma Partnerships And Injectable Demand Will Expand Global Reach
Fair Value: US$8.75 12.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lifecore Biomedical, Inc. Key Details
Last Reported Earnings
May 25, 2025
Next Reporting Earnings
n/a
- -1.18
- 31.27%
- -34.42%
- 275.0%
About LFCR
- Founded
- 1965
- Employees
- 406
- CEO
- WebsiteView website
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of hyaluronate acid (HA) in bulk form, as well as formulated and filled syringes, cartridges, and vials for injectable products used in treating a range of medical conditions and procedures. Its product development services include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
